AGENDA
| Activity | Time |
| Registration Poster installation Exhibitors’ setup |
09:00 – 14:00 |
| SPEAKER | TITLE | TIME |
| Prof. Paolo Martelli (University Rector) Francesca Buttini (University of Parma) |
Conference opening: Welcome and Introduction | 14:00-14:20 |
|
NEW PARADIGMS IN LUNG DELIVERY
|
||
|
Chairs: Ruggero Bettini and Joanne Peart |
||
|
Keynote Speaker: Melanie Ott |
In the Air Around Us: Understanding and Outpacing Viral Threats | 14:20 – 15:00 |
| Fabien Barbirato (Sanofi) |
IBeyond the Needle: Engineering Novel mRNA Lipid Nanoparticle Formulations for Respiratory Mucosal Vaccination | 15:00 – 15:25 |
| Philip Kwok (University of Sidney) |
Probiotic-bacteriophage aerosols for treating bacterial lung infections |
15:25 – 15:50 |
|
COFFEE BREAK + POSTER SESSION |
||
|
Chairs: Julie Suman and Francesca Buttini |
||
| Andrea Casazza (Chiesi Farmaceutici) |
Disease‑First, a Strategy for Next‑Generation Inhaled Medicines | 16:30 – 16:55 |
| Michael Goller (TranspireBio) |
Expanding Inhalation Therapies beyond Asthma and COPD | 16:55 – 17:20 |
| Lucas Silva (Aptar Pharma) |
Breaking Barriers in Biologics Delivery: Advanced Nasal and Pulmonary Delivery of Large Proteins and Nucleic Acids | 17:20 – 17:30 |
| Anselm Ebert (H&T Presspart) |
Navigating Inhalation Trends: Delivering Innovative, Sustainable Device Solutions | 17:30 – 17:40 |
|
WELCOME RECEPTION (17:40 – 19:00) |
||
|
AEROSOLS OF LUNG INFECTION
|
||
|
Chairs: Irene Rossi |
||
| Sara Maloney (RTI International) |
Formulation Strategies for Inhaled NTM Therapies | 09:00 – 09:25 |
| Mercedes Gonzalez-Huarrero (Colorado State University) |
Preclinical development of aerosol therapy for M. abscessus pulmonary disease | 09:25 – 09:50 |
| Rahul Kumar Verma (Institute of Nano Science and Technology Mohali) |
Inhalable self-propelled Autonomous micro motors for Tuberculosis therapeutics |
09:50 – 10:05 |
| Miles Kottman (Bespak) |
Beyond the propellant: taking the next step in low carbon pMDIs | 10:05 – 10:15 |
|
COFFEE BREAK + POSTER SESSION |
||
|
PRESSURISED METERED DOSE INHALES AT 70
|
||
|
Chairs: Daniela Traini and Geraldine Venthoye |
||
| John Pritchard (Inspiring Strategies) |
Is the transition to lower global-warming propellants on schedule? | 11:00 – 11:20 |
| Sheryl Johnson (Orbia) |
pMDI Formulation at 70: Unlocking HFA 152a for the Next Generation | 11:20 – 11:30 |
| Mark Boelens (Solstice) |
Evolving Regulatory Landscape for the Adoption of Low Global Warming Potential (LGWP) Propellants |
11:30 – 11:40 |
| Paul Young – David Lewis (Oz-Uk Ltd) |
From First Principles to Representative Performance: pMDIs in the Low-GWP Era | 11:40 – 12:00 |
| Stephen Stein (CGT Pharma Consulting) |
Developing Suitable Suspension MDI Formulations in LGWP Propellants | 12:00 – 12:20 |
| ROUND TABLE |
pMDIs at 70: What does the future hold? John Pritchard – Nick Smalley (Kindeva) – Stephen Stein – Paul Young |
12:20 – 13:00 |
|
LIGHT LUNCH + POSTER SESSION |
||
|
MUCUS-PENETRATING PARTICLES AND RNA DELIVERY
|
||
|
Chairs: Alessandro Fioni and Ben Forbes |
||
| Keynote Speaker Justin Hanes (Johns Hopkins University) |
The Airway Mucus Barrier and How to Overcome it | 14:15 – 14:55 |
| Rémi Rosière (InhaTarget Therapeutics) |
Lung Delivery of Nucleic Acid–Loaded Lipid Nanoparticles to Tackle High Unmet Needs in Respiratory Medicine | 14:55 – 15:20 |
| Koen Raemdonck (Ghent University) |
Inhalable RNA formulations for pulmonary diseases | 15:20 – 15:45 |
| Franziska Dahlmann (Fraunhofer ITEM, Hannover) |
Translational development of an inhaled palmitoyl-conjugated antiviral siRNA against Human Parainfluenza virus infection |
15:45 – 16:00 |
|
COFFEE BREAK + POSTER SESSION |
||
| ROUND TABLE | 1000 Years of Experience, 16 Years of Progress: What Still Remains? Chair: Jayne Hastedt Per Bäckman (Emmace AB) – Andy Clark (InStatin Inc., remote) – Paolo Colombo (PlumeStars) – Carsten Ehrhardt (Trinity College Dublin) – Ben Forbes (King’s College London) – Anthony Hickey (RTI International) – John Patton (Kindeva) – Jeffrey Weers (PhIAT, remote) |
16:30 – 17:30 |
|
NEW PERSPECTIVES ON AIRWAY INFLAMMATION AND CHRONIC COUGH
|
||
|
Chairs: Stefano Aliberti and Gaetano Caramori |
||
| Keynote Speaker David Edwards (SC Therapeutics) |
Airway inflammation and hypertension | 09:00 – 09:40 |
| Federico Lavorini (Careggi University Hospital) |
Clinical Aspects and Pathophysiology of Chronic Cough | 09:40 – 10:05 |
| Alyn Morice (University of Hull) |
Chronic Cough Management: From Current Treatments to Emerging Therapies | 10:05 – 10:30 |
| Diletta Mandrioli (University of Parma) |
Carcainium Dry Powder Inhaler for Prolonged Chronic Cough Treatment | 10:30 – 10:45 |
|
COFFEE BREAK + POSTER SESSION |
||
| Stefano Aliberti (Humanitas Research Hospital) |
Non–cystic fibrosis bronchiectasis and emerging therapeutic strategies | 11:30 – 11:55 |
| Valentina Fainardi (Parma University Hospital) |
Comparative Profiling of the Airway and Gut Microbiota in Cystic Fibrosis and Primary Ciliary Dyskinesia | 11.55 – 12:15 |
| Philip Kuehl (Aptar Pharma) |
Preclinical Tools for Advancing Pulmonary and Nasal Drug Products | 12:15 – 12:35 |
| Murat Ali (Phillips Medisize) |
Enabling Therapies Today and Tomorrow: Demonstrating the Versatility of Blister-Based Dry Powder Inhalers for Current and Future Drug Delivery | 12:35 – 13:00 |
|
LIGHT LUNCH + POSTER SESSION |
||
NASAL DELIVERY OF BIOLOGICS AND RNA |
||
|
Chairs: Regina Scherliess & Fabio Sonvico |
||
| Nathalie Heuzé-Vourc’h (National Institute of Biomedical Research) |
Exploring Intranasal Delivery of Anti-Infective Antibodies | 14:30 – 14:55 |
| Chantelle Ahlenstiel (Kirby Institute) |
Respiratory delivery of antiviral RNA therapeutics | 14:55 – 15:20 |
| Katharina Schindowski (Biberach University) |
Intranasal nose-to-brain delivery of a monoclonal antibody with a controlled release drug delivery system: proof-ofconcept and pharmacokinetic studies in mini pigs | 15:20 – 15:45 |
|
COFFEE BREAK + POSTER SESSION |
||
|
Chairs: Teresa M. Carvajal and Daniela Traini |
||
| Brianna Walz (University of Toronto) |
Optimization and Mechanistic Characterization of Intranasal mRNA-Lipid Nanoparticles for Systemic Protein Secretion | 16:15 – 16:30 |
| Ana Fortuna (University of Coimbra) |
From First Principles to Measured Performance: pMDIs in the Low-GWP Era | 16:30 – 16:50 |
| Francesca Buttini (University of Parma) |
CLOSING REMARKS | 16:45 – 17:00 |
|
GALA DINNER |
||
CONFIRMED PLENARY SPEAKERS
David Edwards
SC Therapeutics, US
Justin Hanes
Johns Hopkins University, US
CONFIRMED INVITED SPEAKERS
Fabien Barbirato
Sanofi, France
Mercedes Gonzalez-Juarrero
Colorado State University, US
Michael Goller
Transpire Bio, US
Philip Kuehl
Aptar Pharma, US
Philip Kwok
University of Sydney, Australia
David Lewis
Oz-UK Ltd, UK
Sara Maloney
RTI International, US
Alyn Morice
University of Hull, UK
John Pritchard
Inspiring Strategies, UK
Koen Raemdonck
Ghent University, Belgium
Rémi Rosière
InhaTarget Therapeutics, Belgium
Katharina Schindowski
Biberach University, Germany
Steve Stein
CGT Pharma Consulting, US
Nathalie Heuzé-Vourc’h
National Institute of Biomedical Research, France
SPEAKERS FROM OUR PLATINUM SPONSORS
Anselm Ebert
H&T Presspart
Mark Boelens
Solstice
Sheryl Johnson
Orbia
Miles Kottman
Bespak
Lucas Silva
Aptar Company
